Inhaled steroids — too much of a good thing?
Authors: Dianne P Goeman, Susan M Sawyer, Michael J Abramson, Kay Stewart, Francis C K Thien, Rosalie A Aroni and Jo A Douglass
Published online: 3 March 2003
To the Editor: Our recent study of patients' priorities for asthma care1,2 provides additional evidence supporting the concerns of Wilson and Robertson in their editorial questioning the possible overuse of inhaled corticosteroids.3
We have reported a qualitative study of 62 individuals who presented to an emergency department at either a central city, suburban or rural hospital, in which we explored individuals' perceptions about their asthma, its care and the impact of asthma on their lives.1,2 We also asked participants to complete a questionnaire on the use of medications and sought to amplify this information by further probing the use of medications in our qualitative data collection.
Of the 82% of participants in our study currently using inhaled corticosteroid medication (51), 30% (16) were taking 1000 μg of fluticasone or equivalent daily and another 19% (10) were taking more than 1500 μg or equivalent. Current product information for fluticasone suggests a maximum dose of 1000 μg twice daily, whereas National Asthma Council (NACA) guidelines recommend that 500 μg fluticasone or equivalent daily may be the upper limit of useful effect.4,5
We also asked patients how long their medication lasted. Eleven (18%) stated that inhaled corticosteroid devices lasted three weeks or less. Use above recommended doses did not only occur for inhaled corticosteroids, but also for symptom controller medications. Twenty-four (35%) of the 31 (50%) patients receiving this medication reported that a device lasted three weeks or less, indicating use above usual recommended doses.
Most patients in our study voiced concerns about the cost of asthma and drug side effects; some adjusted their medication use to manage these issues.1 In such individuals, high use or overuse of preventive and controller medication would increase both costs and side effects, partly explaining these patients' concerns.
Doctors may be overprescribing inhaled corticosteroid medication because there is a discrepancy between dosages recorded in published drug information and newer recommendations for optimal inhaled corticosteroid dose.4,5 Our findings show that, in some patients, the risks associated with the use of inhaled corticosteroids are likely to be compounded by using them at higher doses than those recommended. Doctors need to be aware of this in managing patients with asthma who have severe symptoms, in whom overuse, rather than underuse, is likely to be a problem.
References
- Goeman D, Aroni R, Stewart K, et al. Patients' views of the burden of asthma: a qualitative study. Med J Aust 2002; 177: 295-299. <eMJA full text>
- Douglass J, Aroni R, Goeman D, et al. A qualitative study of action plans for asthma. BMJ 2002; 324: 1003-1007. i1082297
- Wilson J, Robertson C. Inhaled steroids — too much of a good thing? The goal is to achieve optimal asthma control with the lowest effective dose. Med J Aust 2002; 177: 288-289. <eMJA full text>
- Asthma management handbook 2002. Melbourne: National Asthma Council, 2002: 43. i1082301
- MIMS Australia 2002. Issue No. 4. Sydney: MediMedia Australia Pty Ltd, 2002: 278. i1082303
Barriers and Facilitators to Timely Detection and Optimal Management of Chronic Wet Cough in Aboriginal Children Across Australia From the Perspectives of Carers of Aboriginal Children: A Qualitative Study
Gloria T. Y. Lau, Pam Laird, Robyn Aitken, Melanie Barwick, Liam Bedford, Emily R. Bowden, Jamie Everingham, Angela Fuery, Reece Griffin, Neha Jain, Mina Kinghorn, Renae Knapp, Gabrielle B. McCallum, Peter Morris, Richard Norman, Peter C. Richmond, Aarti Saiganesh, Slade Sibosado, Cameron Taylor, Maree Toombs, Roz Walker, Joan Wilson, Anne B. Chang, André Schultz
Barriers and Facilitators to Timely Detection and Optimal Management of Chronic Wet Cough in Aboriginal Children Across Australia From the Perspective of Health Care Providers: A Qualitative Study
Gloria T. Y. Lau, Pamela Laird, Robyn Aitken, Melanie Barwick, Liam Bedford, Emily R. Bowden, Corey Dalton, Jamie Everingham, Angela Fuery, Reece Griffin, Neha Jain, Mina Kinghorn, Renae Knapp, Gabrielle B. McCallum, Peter Morris, Richard Norman, Peter C. Richmond, Aarti Saiganesh, Slade Sibosado, Maree Toombs, Roz Walker, Joan Wilson, Anne B. Chang, André Schultz
Respiratory Syncytial Virus Disease Burden and Evidence Gaps in Australia Before Immunisation Introduction: A Retrospective Population-Based Study Using 2016–2019 Hospitalisation and 2023 Laboratory Surveillance Data
Chisato Imai-Boulter, Jean Li-Kim-Moy, Clayton Chiu, Sanjay Jayasinghe, Kristine Macartney
Not Gone but Often Forgotten: Action Needed to Address Tuberculosis in Aboriginal and Torres Strait Islander Communities
Nikkita Joshua, Emma L. Smith, Eunice (Cheeky) Love, Christopher P. Lowbridge, Nicole Tukana, Amy Bowden, Megan A. Campbell, Dawn Casey, James Ward
Uneven Ground: Survival Differences Among Victorian Lung Cancer Patients by Location of Residence (2011–2023): A Retrospective Cohort Study
Evangeline Samuel, Eldho Paul, Mike Lloyd, Sanuki Tissera, Craig Underhill, Sagun Parakh, Phillip Parente, Inger Olesen, Javier Torres, Katharine See, Gavin M. Wright, David Langton, Thomas John, Matthew Conron, James Bartlett, Nicola Atkin, Nikolajs Zeps, Susan V. Harden, Wasek Faisal, John R. Zalcberg, Rob G. Stirling
Treatment and Survival Outcomes for Indigenous and Non-Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross-Sectional Cohort Study
Melanie Wong, Mike Lloyd, Jessie Zeng, Sanuki Tissera, Kalinda E. Griffiths, Justine Clark, Jonathan Gillies, Lisa Briggs, Jacqueline Lesage, Tom Wood, Craig Underhill, Sagun Parakh, Louis B. Irving, Wasek Faisal, Rob Blum, Gary E. Richardson, Phillip Parente, Michelle Caldecott, Inger Olesen, Javier Torres, Evangeline Samuel, Christopher Lyne, Katharine See, David Langton, Thomas John, Gavin Wright, Matthew Conron, James Bartlett, Golsa Adabi, Maggie Moore, Susan Harden, Zoe K. McQuilten, John R. Zalcberg, Rob Stirling